News Partner's Bizengri is first drug for rare, aggressive cancer Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.
News Merus grabs first-in-class US approval for NRG1 cancer drug Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.